GSK has no plans to appeal and has no further ... we are disappointed that these patients will not have access to Trelegy Ellipta for asthma, we remain committed to supporting them with our ...

Trelegy Ellipta got its first US approval in September ... Trelegy was approved in Europe last week in COPD maintenance therapy. But GSK is already seeking an expanded US label for maintenance ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 3 min 2 sec ago By Ewan Larkin - 39 min 35 sec ago By Matt McCain - 3 hours 9 min ago By Lenore Moritz - 3 hours 34 min ago ...

GSK reported core earnings of $1.27 per American ... This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand.

GSK plc GSK reported adjusted earnings of 72 ... Anoro Ellipta, Breo Ellipta and Trelegy Ellipta and the continued post-pandemic recovery of the antibiotic market outside the United States.

GSK plc GSK reported third-quarter 2024 core ... the upside was primarily driven by solid sales growth of asthma inhaler ...

GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased 14% to 2.97 billion pounds. HIV drug revenues increased by 8% to 1.75 billion ...